Cargando…
Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
BACKGROUND: Third-generation aromatase inhibitors (AIs) are the mainstay of treatment in hormone receptor (HR)-positive breast cancer. Even though it is considered to be a well-tolerated therapy, AI-induced musculoskeletal symptoms are common and may be accused for treatment discontinuation. Recentl...
Autores principales: | Skafida, Efthymia, Andrikopoulou, Angeliki, Terpos, Evangelos, Markellos, Christos, Moustafa, Savvina, Pectasides, Dimitrios, Dimopoulos, Meletios-Athanasios, Zagouri, Flora, Vassilopoulos, Dimitrios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247331/ https://www.ncbi.nlm.nih.gov/pubmed/37293258 http://dx.doi.org/10.1155/2023/3614296 |
Ejemplares similares
-
Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021) -
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021) -
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
por: Zagouri, Flora, et al.
Publicado: (2021) -
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
por: Liontos, Michalis, et al.
Publicado: (2021) -
MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)